PROGRAMME OF LIVE SESSIONS: CEST timing

The programme below will take place live. This time schedule corresponds to CEST timing. Click here to adapt the CEST time schedule to your own time zone.

If you want to ask questions during the Panel Discussions and Round Tables or if you want to test your knowledge and vote during Interactive Case presentations and debates, please make sure that you join us at the times indicated below.

Please also note that the Meet the Expert sessions and the Mentored Poster Walk will take place 100% live. To interact you must be online at the times indicated in the programme below.

Thank you for joining us. We wish you a good meeting

5th Translational Research Conference
Multiple Myeloma
October 8-11, 2020
Chairpersons: Kenneth C. Anderson, Maria-Victoria Mateos, Philippe Moreau

Thursday, October 8th, 2020

14:00–14:15 Welcome

SESSION I – Smoldering myeloma
Chair: Maria-Victoria Mateos (Salamanca)

14:15-14:20 Introduction Maria-Victoria Mateos (Salamanca)
14:20-14:35 Clonal evolution in smoldering myeloma Madhav V. Dhodapkar (Atlanta)
14:35-14:50 High-risk smoldering: what is the exact definition? Irene Ghobrial (Boston)
14:50-15:05 Clinical trials Maria-Victoria Mateos (Salamanca)
15:05-15:12 Selected brief oral communication
15:12-15:40 Panel discussion
15:40-15:50 Coffee Break
### SESSION II – Diagnosis of multiple myeloma

**Chair:** Hervé Avet-Loiseau (Toulouse)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:50-15:55</td>
<td>Introduction</td>
<td>Hervé Avet-Loiseau (Toulouse)</td>
</tr>
<tr>
<td>15:55-16:10</td>
<td>Diagnostic criteria and initial workup</td>
<td>Shaji Kumar (Rochester)</td>
</tr>
<tr>
<td>16:10-16:25</td>
<td>Genetics and risk assessment</td>
<td>Hervé Avet-Loiseau (Toulouse)</td>
</tr>
<tr>
<td>16:25-16:40</td>
<td>Frailty assessment at diagnosis</td>
<td>Alessandra Larocca (Turin)</td>
</tr>
<tr>
<td>16:40-16:47</td>
<td><strong>Selected brief oral communication</strong></td>
<td>Speaker</td>
</tr>
<tr>
<td>16:47-17:15</td>
<td><strong>Panel discussion</strong></td>
<td></td>
</tr>
<tr>
<td>17:25</td>
<td><strong>Mentored Poster Walks</strong></td>
<td></td>
</tr>
</tbody>
</table>

---

### Friday, October 9th, 2020

**13:20-14:20**  Possible slot for a satellite symposium

**SESSION III – Frontline therapy in patients not eligible for autologous stem cell transplantation**

**Chair:** Sonja Zweegman (Amsterdam)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:25-14:30</td>
<td>Introduction</td>
<td>Sonja Zweegman (Amsterdam)</td>
</tr>
<tr>
<td>14:30-14:45</td>
<td>Overview phase 3 trials and newly approved treatments</td>
<td>Xavier Leleu (Lille)</td>
</tr>
<tr>
<td>14:45-15:00</td>
<td>Fit vs Frail: the European point of view</td>
<td>Sonja Zweegman (Amsterdam)</td>
</tr>
<tr>
<td>15:00-15:15</td>
<td>Fit vs frail: The point of view of North America</td>
<td>Hira Mian (Hamilton)</td>
</tr>
<tr>
<td>15:15-15:22</td>
<td><strong>Selected brief oral communication</strong></td>
<td>Speaker</td>
</tr>
<tr>
<td>15:22-15:50</td>
<td><strong>Panel discussion</strong></td>
<td></td>
</tr>
<tr>
<td>15:50-16:00</td>
<td><strong>Coffee break</strong></td>
<td></td>
</tr>
</tbody>
</table>

**SESSION IV – Frontline therapy in patients eligible for autologous stem cell transplantation**

**Chair:** Philippe Moreau (Nantes)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-16:05</td>
<td>Introduction</td>
<td>Philippe Moreau (Nantes)</td>
</tr>
<tr>
<td>16:05-16:20</td>
<td>Overview of European trials</td>
<td>Philippe Moreau (Nantes)</td>
</tr>
<tr>
<td>16:20-16:35</td>
<td>US point of view on new trials (including explanation of why HSCT is not proposed frontline)</td>
<td>Paul Richardson (Boston)</td>
</tr>
</tbody>
</table>
16:35-16:50 Maintenance therapy
  Graham Jackson (Newcastle)

16:50-16:57 Selected brief oral communication
  Speaker

16:57-17:25 Panel discussion and/or controversial debates

17:30-18:30 3 Simultaneous Meet the Expert sessions

1. Assessments for MRD evaluation
   Francesca Gay (Turin), TBA

2. Definition and identification of high-risk Myeloma
   Hervé Avet-Loiseau (Toulouse), Saad Usmani (Charlotte)

3. Immunoprofiling in Myeloma
   Madhav Dhodapkar (Atlanta)*, Bruno Paiva (Pamplona)

Saturday, October 10th, 2020

09:30-10:30 Possible slot for a satellite symposium

SESSION V – MRD and the microenvironment
Chair: Elena Zamagni (Bologna)

10:35-10:40 Introduction
  Elena Zamagni (Bologna)

10:40-10:55 MRD and imaging
  Elena Zamagni (Bologna)

10:55-11:10 MRD and immune profiling (differences in terms of response)
  Bruno Paiva (Pamplona)

11:10-11:25 How MRD assessment will impact clinical management
  Noemi Puig (Salamanca)

11:25-11:32 Selected brief oral communication
  Speaker

11:32-12:00 Panel discussion

12:00-13:40 Lunch

12:30-13:30 SATELLITE SYMPOSIUM:
  Multiple Myeloma: Toward the Implementation of Measurable Residual Disease (MRD) in Clinical Practice
  Speakers: Maria-Victoria Mateos (Salamanca), Jeffrey Wolf (San Francisco)

This symposium is organised and funded by Adaptive Biotechnologies
SESSION VI – Relapsed multiple myeloma
Chair: Kenneth C. Anderson (Boston)

13:40-13:45 Introduction Kenneth C. Anderson (Boston)
13:45-14:00 How to sequence in 1st and 2nd relapse? Meletios Dimopoulos (Athens)
14:00-14:15 Beyond 2nd relapse Saad Usmani (Charlotte)
14:15-14:30 Overview immune therapies? Noopur Raje (Boston)
14:30-14:37 Brief Oral Communication Speaker
14:37-15:05 Panel discussion

SESSION VII – The future: recent clinical trials in relapse
Chair: Hermann Einsele (Würzburg)

15:05-15:10 Introduction Hermann Einsele (Würzburg)
15:10-15:25 Novel targeted therapies (not immune) Shaji Kumar (Rochester)
15:25-15:40 Novel immunotherapies (part 1) Hermann Einsele (Würzburg)
15:40-15:55 Novel immunotherapies (part 2) Sagar Lonial (Atlanta)
15:55-16:02 Brief Oral Communication Speaker
16:02-16:25 Panel discussion and/or controversial debates

16:25-16:35 Coffee break

16:35-17:35 4 Simultaneous Breakfast Meet the Expert

1. Management of MM patients Len-refractory Philippe Moreau (Nantes), Katja Weisel (Hamburg)*
2. How are we going to select the ideal MM patient for CAR-T? Mohamad Mohty (Paris), Nikhil Munshi (Boston)
3. Are there new targets in Myeloma beyond CD38? Kenneth C. Anderson (Boston), Paul Richardson (Boston)*
4. Therapeutic strategies targeting the tumor microenvironment Irene Ghobrial (Boston), TBA
10:15-11:15  Possible slot for a satellite symposium

SESSION VIII – Data management issues
Chair: Mohamad Mohty (Paris)

11:20-11:25  Introduction
Mohamad Mohty (Paris)

11:25-11:40  Access to innovative drugs: pharma-academia cooperation
Mohamad Mohty (Paris)

11:40-11:55  iStopMM-a nationwide screening for MGUS and myeloma and early treatment of smoldering myeloma
Sigurdur Kristinsson (Reykjavik)

11:55-12:10  Bureaucracy is strangling clinical research
Steven Le Gouill (Nantes)

12:10-12:25  EMA vs FDA approvals: differences, why?
Beatriz Flores (London)*

12:25-12:32  Brief Oral Communication
Speaker

12:32-13:00  Panel discussion

13:00-13:55  Lunch

SESSION IX – Plasma cell disorders
Chair: Bertrand Arnulf (Paris)*

13:55-14:00  Introduction
Bertrand Arnulf (Paris)*

14:00-14:15  Waldenstrom’s disease
Jorge Castillo (Boston)

14:15-14:30  POEMS
Arnaud Jaccard (Limoges)

14:30-14:45  Monoclonal gammopathy of clinical significance
Bertrand Arnulf (Paris)*

14:45-15:00  Amyloidosis
Giampaolo Merlini (Pavia)

15:00-15:07  Brief Oral Communication
Speaker

15:07-15:35  Panel discussion

MEETING CLOSURE

*Pending confirmation